# Aeovian Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aeovian-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Berkeley, US
- Website: www.aeovian.com/
- Total disclosed funding: $124M
- Latest round: Series B (Nov 18, 2025)
- Investors on record: 12

## About

Founded in 2012 by Stelios Tzannis (COO) and based in California, US, Aeovian Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutics for the treatment of rare and age-related diseases. In November 2025, Aeovian Pharmaceuticals, Inc. raised USD 55 million in series B funding co-led by new investors Luma Group and CTI Life Sciences Fund, with participation from other new investors Foresite Capital, SymBiosis, TSC Alliance Endowment Fund and Wilson Sonsini Goodrich & Rosati. Returning investors Apollo Health Ventures, Hevolution, Sofinnova Investments, and venBio also participated in the round. The series A funding values Aeovian Pharmaceuticals, Inc. at USD 120.88 million post-money. As of 2024, the company is led by its CEO, Allison J. Hulme.

The company specializes in developing targeted, selective small molecules to restore cellular metabolic quality control. The firm’s primary goal is to address the dysregulated growth and hyperactive signaling found in certain rare genetic and age-related diseases. Aeovian’s development candidate, AV078, is the CNS penetrant selective mTORC1 inhibitor, which is in Phase 1 clinical trials for treating tuberous sclerosis complex (TSC) refractory epilepsy. In addition, the company has developed a proprietary library of potent and selective inhibitors of mTORC1 and CD38, targeting multiple rare and age-related diseases.

The organization plans to use the March 2024 funding to accelerate the Phase 1 clinical trial in healthy volunteers and get ready for the beginning of a Phase 2 clinical trial in adult and pediatric TSC refractory epilepsy patients.

## Funding rounds

- Series B, Nov 18, 2025, $55M — Sofinnova Investments, CTI Life Sciences, Foresite Capital, Wilson Sonsini Goodrich & Rosati, VenBio, Apollo Health Ventures, SymBiosis Capital Management, Hevolution Foundation, Luma Group
- Series A, Mar 28, 2024, $50M — Sofinnova Investments, Evotec SE, b2venture, VenBio, Apollo Health Ventures, Hevolution Foundation
- Series A, Sep 24, 2019, $19M — Sofinnova Investments, Evotec SE, VenBio, Apollo Health Ventures
- Seed, Mar 1, 2019 — FJ Labs
- Seed, May 15, 2018 — FJ Labs
- Seed, Jul 20, 2017 — FJ Labs

## Investors

- FJ Labs (https://capitalatlas.ai/funds/fj-labs) — Seed
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series A, Series B
- Evotec SE — Series A
- VenBio (https://capitalatlas.ai/funds/venbio) — Series A, Series B
- Apollo Health Ventures (https://capitalatlas.ai/funds/apollo-health-ventures) — Series A, Series B
- b2venture (https://capitalatlas.ai/funds/b2venture) — Series A
- Hevolution Foundation — Series A, Series B
- CTI Life Sciences (https://capitalatlas.ai/funds/cti-life-sciences) — Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B
- Wilson Sonsini Goodrich & Rosati — Series B
- SymBiosis Capital Management (https://capitalatlas.ai/funds/symbiosis-capital-management) — Series B
- Luma Group (https://capitalatlas.ai/funds/luma-group) — Series B